CA-CEPTON-TECHNOLOGIES
19.8.2021 15:02:13 CEST | Business Wire | Press release
Leading lidar solutions provider Cepton received two recognitions at Tech.AD Europe this year for its innovations, adding to the company’s growing portfolio of award-winning lidar solutions across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005247/en/
Tech.AD is a leading technical conference in Europe focused on technologies for autonomous driving (AD) and the advancements of artificial intelligence (AI) technology in the automotive industry. The annual Tech.AD Europe Award exclusively honors "extraordinary projects in the automotive industry and celebrates exceptional solutions & innovations." Awards are announced after submissions are rated by a jury of some of the top subject matter experts in Europe.
Cepton was recognized in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies for its Nova lidar . Second place award-winner in this category, Nova is a pathbreaking miniature, wide field of view (FOV) lidar sensor for near-range perception in advanced driver assistance systems (ADAS), autonomous vehicle (AV) and autonomous ground vehicle (AGV) applications. Nova provides an attractive combination of performance, compactness, FOV coverage and affordability and enables a range of use cases such as high-accuracy blind spot detection, small object detection, automated park assist and free space estimation around the vehicle.
Another award was given to a Cepton lidar-enabled smart cities project - Traffic Monitoring as Source of Training Data for Autonomous Vehicles - by Cepton partner ALP.Lab , which won the top prize in the category of Most Advanced Real-Life Testing & Simulation Techniques in Autonomous Driving . Deployed in the City of Graz, the ALP.Lab project utilizes Cepton’s Helius ® Smart Lidar System and Vista® -P lidars to enable advanced, real-time, 3D traffic and pedestrian analytics. According to ALP.Lab, “the enormous amount of time and expense involved in collecting training data for ADAS/AD development can be dramatically reduced by this new and sustainable lidar perception based technique focused on specific roads and environments likely to generate the most diverse and difficult driving environments.”
The Tech.AD Europe awards represent a continuation of past recognitions of Cepton’s lidar innovations. Previously, Cepton received awards for its lidar solutions across multiple applications, including the AUVSI XCELLENCE in Innovation Award in 2019 for the Sora™ lidar, the Security Today New Product of the Year Award in 2019 in the Perimeter Protection category for the first generation of Helius® known as Vista-Edge, the Autonomous Vehicle Technology ACES Award in 2020 jointly with Cepton partner Dataspeed for the Vista® -P lidar, and the CES Innovation Award in 2020 in two categories – Smart Cities and Tech for a Better World – for the Helius® Smart Lidar system, that also includes our Vista® -P lidars.
Dr. Jun Pei, CEO of Cepton, said: “The awards at Tech.AD Europe were not only based on jury selection, but also based on the voting of all of the conference attendees representing leading automotive OEMs, autonomous vehicle companies, Tier 1 suppliers, and other R&D organizations worldwide. We are grateful for this recognition and what it represents for the continued innovation we are bringing to market using our MMT® lidar technology. Increasingly, the role of Cepton lidars in the future of mobility is becoming clear worldwide and we are pleased to work with global partners such as ALP.Lab in advancing safety and autonomy.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in North America, Germany, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom